| Patents |
| |
|
| COR-1: |
Publication: WO 96/04912
US Patent: 5,849,740
Granted 15th December 1998
EPO: Pending Description
Use of cortisol inhibitors (ketoconazole and its derivatives) for treating
Type 2 Diabetes/Metabolic Syndrome.
Cortendo’s first patent, specifically targeting the therapeutic
use of ketoconazole and derivatives
|
|
| COR-1 US-2: |
US Patent: 6,166,017
Granted 26th December 2000. Description:
Use of cortisol inhibitors for treating Type 2 Diabetes/Metabolic Syndrome.
An extension of COR-1 protecting all current and future compounds
acting at any point on the hypothalamo-pituitary-adrenal (HPA) axis
to down-regulate cortisol effects in order to treat Type 2 Diabetes/Metabolic
Syndrome
|
|
| COR-2: |
Publication: WO 96/38179
US Patent: Approved, Not yet issued
EPO: Pending Description:
Use of cortisol agonists as a diagnostic tool.
This patent application aims to protect all current and future
compounds acting at any point along the HPA axis with a cortisol-like
effect as a basis for a simple test to find patients in the early stages
of metabolic disease
|
|
| COR-3: |
Publication: WO 98/36770
US Patent: 6,247,582
EPO: Pending Description
Combination of cortisol synthesis inhibitors and growth hormone.
This patent application aims to protect the use of all current and
future cortisol inhibitors acting at any point along the HPA axis to
down-regulate cortisol effects in combination with growth hormone to
treat Type 2 Diabetes/ Metabolic Syndrome.
This is an extended therapeutic concept which reflects the disturbances
in growth hormone that can occur in these disease states.
|
|
| COR-4: |
Publication: WO 01/01971 Description
Use of cortisol synthesis inhibitors for treating heart failure.
This patent application aims to protect the use of all current
and future cortisol inhibitors acting at any point along the HPA axis
to down-regulate cortisol effects in the treatment of heart failure
arising from all causes.
|
|
| COR-5: |
Publication: WO 01/52833 Description:
Pharmaceutical formulations for the delivery of cortisol synthesis inhibitors.
This patent application aims to protect the pharmaceutical formulations
designed to deliver cortisol synthesis inhibitors to coincide with the
normal diurnal secretion profile of cortisol.
|
|
| COR-8 |
Application: GB 0118299.7
filed on 26th July 2001. Description:
Use of first ketoconazole derivative in a pharmaceutical formulation
for treating Type 2 Diabetes/Metabolic Syndrome.
This patent application aims to protect the use of an enantiomer
of ketoconazole in a pharmaceutical formulation designed to deliver
cortisol synthesis inhibitors to coincide with the normal diurnal secretion
profile of cortisol
|
|
| COR-9 |
Application: GB 0118300.3
filed on 26th July 2001. Description:
Use of second ketoconazole derivative in a pharmaceutical formulation
for treating Type 2 Diabetes/Metabolic Syndrome.
This patent application aims to protect the use
of a second enantiomer of ketoconazole in a
pharmaceutical formulation designed to deliver
cortisol synthesis inhibitors to coincide with the
normal diurnal secretion profile of cortisol.
|
| |
